NewAmsterdam Pharma (NAMS) Operating Leases (2021 - 2025)

NewAmsterdam Pharma has disclosed Operating Leases across 5 years of filings, most recently posting $66000.0 for Q4 2025.

• Operating Leases for Q4 2025 came in at $66000.0, down 67.33% year-over-year; the trailing twelve-month figure through Dec 2025 was $66000.0 (down 67.33% YoY), and the FY2025 annual result was $66000.0, down 67.33% from the prior year.
• Operating Leases came in at $66000.0 for Q4 2025 at NewAmsterdam Pharma, down from $85000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $328000.0 in Q2 2024 to a low of $57133.9 in Q4 2022.
• The 5-year median for Operating Leases is $114990.4 (2021), against an average of $144080.6.
• Across the five-year window, Operating Leases soared 370.65% in 2024 and slumped 68.6% in 2025, its largest moves.
• NewAmsterdam Pharma's Operating Leases stood at $126980.8 in 2021, then plunged by 55.01% to $57133.9 in 2022, then climbed by 21.98% to $69691.2 in 2023, then jumped by 189.85% to $202000.0 in 2024, then sank by 67.33% to $66000.0 in 2025.
• The last three Operating Leases figures came in at $66000.0 (Q4 2025), $85000.0 (Q3 2025), and $103000.0 (Q2 2025), per Business Quant data.